Stereotactic Magnetic Resonance Guided Radiation Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adrenal Metastases
- Liver Metastases
- Lung Cancer
- Metachronous Nodal Metastases
- Oligoprogressive Nodal Metastases
- Pancreas Cancer
- Prostate Cancer
- Renal Cancer
- Synchronous Nodal Metastases
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: All participants will be assigned to one treatment arm only depending on their cancer type, and will be taken off study once treatment and follow up are complete.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer. The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer. In this research study...
This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer. The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer. In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.
Tracking Information
- NCT #
- NCT04115254
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jonathan Leeman, MD Brigham and Women's Hospital
Get Well Soon